DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneSMAvoice.com | ||
If you'd like to unsubscribe and stop receiving these emails click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Roche’s Evrysdi Offers Survival Benefits in Babies With SMA
Roche has reported three-year findings from the FIREFISH clinical trial, where its Evrysdi (risdiplam) demonstrated durable improvements in survival and motor milestones in infants with symptomatic Type 1 spinal muscular atrophy (SMA). A survival motor neuron 2 (SMN2) splicing modifier, Evrysdi is intended for treating SMA caused by mutations in chromosome 5q that lead to the deficiency of SMN protein. It is given as daily at-home doses in liquid form through the mouth or using a feeding tube.
Evrysdi can boost and sustain the SMN protein production in the central nervous system (CNS) and peripheral tissues, to treat SMA. The open-label, two-part trial in infants with Type 1 SMA of the age one to seven months at the time of enrolment had two parts. Part 1 was a dose-escalation trial that enrolled 21 infants to evaluate the safety profile of risdiplam in infants and detect the dose for Part 2 as its primary goal.
Related Content
-
EducationCell-Penetrating Peptide-Conjugated Morpholino Rescues SMA in a Symptomatic Preclinical ModelSpinal muscular atrophy (SMA) is a motor...
-
People & PlacesClaire Altman Heine FoundationThe Claire Altman Heine Foundation (CAHF...
-
EducationIdentification of Specific Gene Methylation Patterns During Motor Neuron Differentiation From Spinal Muscular Atroph...Spinal muscular atrophy is a progressive...
-
EducationAdult-Onset Non-5q Proximal Spinal Muscular Atrophy: A Comprehensive ReviewBackground: Adult-onset spinal muscular ...
-
EducationPatient and Caregiver Treatment Preferences in Type 2 and Non-Ambulatory Type 3 Spinal Muscular Atrophy: A Discrete ...Background: Spinal muscular atrophy (SMA...
-
People & PlacesConnie Wolford, MSN, FNP-BCConnie Wolford, MSN, FNP-BC is an advanc...
-
EducationLooking After Your Child Who Has Had a Recent Diagnosis of SMA Type 3Your child should receive care from memb...
send a message
Reset password
password changed successfully!
please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent
a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent
an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.
If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!
Log in
This feature is only available to members.
you haven't confirmed your email address yet. resend confirmation email